- The stock price of Aquestive Therapeutics (AQST) increased by 17.6% today. This is why.
The stock price of Aquestive Therapeutics (AQST) increased by 17.6% today.
Why: Bullish research report
Price target: $8.50
Analyst: Oppenheimer analyst Francois Brisebois
Brisebois pointed out that Aquestive Therapeutics is focused on the development and commercialization of products with its proven PharmFilm technology for anaphylaxis and epilepsy. And as a testament to its platform’s credibility, Aquestive Therapeutics currently has “five FDA-approved products focused on CNS (largest product is Suboxone: blockbuster at peak).”
Plus Brisebois also cited the company’s recent CEO transition, which could lead to an inflection point with the development of AQST-109 (sublingual film epinephrine for anaphylaxis) as its main value driver.
And Brisebois noted that despite Libervant’s (buccal film diazepam for refractory seizures) delays with the FDA, they believe the company’s current revenues alone are underappreciated at this stock price.